Cancer Family
Mesothelial Neoplasm
CI-CAN-00000028Explore in graph →
Non-malignant108 active trials4 approved drugs13 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000028Explore in graph →
Clinical trials
521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT04940637 | UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC(UNITO-001) | unknown | Phase 2 | 70 | University of Turin, ItalyOTHER | 1 | May 12, 2023 |
| clinicaltrials |
| NCT05819580 | Studying the Clinical Trial Experiences of Patients With Mesothelioma | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Apr 25, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT04115111 | Diadem to Investigate the Activity and Safety of Durvalumab(Diadem) | completed | Phase 2 | 57 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05698238 | Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours(CAMP1) | not yet recruiting | Phase 1 | 50 | Mabpro, a.s.INDUSTRY | 0 | Mar 15, 2023 | clinicaltrials |
| NCT00651456 | Mesothelioma Avastin Plus Pemetrexed-cisplatin Study(MAPS) | completed | Phase 2 / Phase 3 | 448 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT01356251 | Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma | completed | N/A | 107 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02414945 | TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients | completed | Phase 1 / Phase 2 | 9 | University Health Network, TorontoOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | recruiting | Phase 1 | 77 | A&G Pharmaceutical Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT02555007 | Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM(NVB Metro) | completed | Phase 1 | 30 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 16, 2022 | clinicaltrials |
| NCT02436733 | Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM | unknown | Phase 2 | 64 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Nov 7, 2022 | clinicaltrials |
| NCT00652574 | Dasatinib in Resectable Malignant Pleural Mesothelioma | completed | Phase 1 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02688166 | Cardiac MRI Biomarker Testing (GCC 1618) | terminated | — | 6 | University of Maryland, BaltimoreOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT02293005 | Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | completed | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT02592551 | MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma | completed | Phase 2 | 24 | Baylor College of MedicineOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT00738582 | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma(Amatuximab) | completed | Phase 2 | 89 | MorphotekINDUSTRY | 5 | Sep 22, 2022 | clinicaltrials |
| NCT01865045 | Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients | completed | — | 150 | Armando Santoro, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02300883 | Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients | completed | — | 100 | Armando Santoro, MDOTHER | 1 | Sep 9, 2022 | clinicaltrials |
| NCT00637624 | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy(NAC-PNP) | terminated | N/A | 69 | Rijnstate HospitalOTHER | 1 | Aug 25, 2022 | clinicaltrials |
| NCT02798536 | Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT05508555 | Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural Mesothelioma | unknown | N/A | 50 | Ain Shams UniversityOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02071862 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | completed | Phase 1 | 210 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 20, 2022 | clinicaltrials |
| NCT04013334 | MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma | unknown | Phase 2 | 12 | Momotaro-Gene Inc.INDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | completed | Phase 1 | 6 | Nagla Abdel KarimOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma | terminated | Phase 1 | 9 | Augusta UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT02385812 | Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma | terminated | Phase 2 | 200 | University of CalgaryOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT03655821 | Dose Individualization of Pemetrexed - IMPROVE-II(IMPROVE-II) | terminated | Phase 4 | 81 | Radboud University Medical CenterOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT03655834 | Dose Individualization of Pemetrexed - IMPROVE-III(IMPROVE-III) | completed | Phase 4 | 10 | Radboud University Medical CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT04088786 | Phase I Trial HIPEC With Nal-irinotecan | completed | Phase 1 | 18 | Stony Brook UniversityOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01655225 | A Study of LY3023414 in Participants With Advanced Cancer | completed | Phase 1 | 156 | Eli Lilly and CompanyINDUSTRY | 3 | Apr 8, 2022 | clinicaltrials |
| NCT02859415 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02838745 | Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM | terminated | Phase 1 | 7 | Baylor College of MedicineOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02464904 | Intrapleural Cryotherapy for Malignant Pleural Mesothelioma | terminated | N/A | 17 | Mayo ClinicOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT04775446 | Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy(MESOIMMUNE) | completed | — | 116 | Centre Hospitalier Intercommunal CreteilOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT04316689 | First-in-human Study of S-588210 (S-488210+S-488211) | completed | Phase 1 | 10 | ShionogiINDUSTRY | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05193006 | Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma | unknown | — | 300 | Hospices Civils de LyonOTHER | 6 | Jan 14, 2022 | clinicaltrials |
| NCT04481672 | Intravenous Magnesium in Patients Receiving Cisplatin | completed | Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT02568449 | Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT03644550 | Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Dec 2, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT05077111 | A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia(VATS) | unknown | Phase 4 | 40 | Mohamed Reda AshourOTHER | 1 | Oct 14, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jun 1, 2023source: clinicaltrials